The Drug Discovery Process: How Do New Glaucoma Medications Come to Market?

  • Michael Bergamini


In the United States of America, no drugs have been approved to treat glaucoma in the past 25 years. The vast majority of drugs in the glaucoma specialist’s armamentarium are indicated for the reduction (or treatment) of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension - or words to that effect. Internationally, the situation is quite different, but this review will focus primarily on how drugs (and more specifically, glaucoma drugs) are discovered and developed for the US market.


Active Pharmaceutical Ingredient Isopropyl Ester Work Breakdown Structure European Public Assessment Report Brimonidine Tartrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Maren TH, Mayer E, Wadsworth BC. Carbonic anhydrase inhibition. I. The pharmacology of Diamox, 2-acetylamino-1,3,4,-thiadizole 5-sulfonamide. Bull Johns Hopkins Hosp. 1954;95:199–243.PubMedGoogle Scholar
  2. 2.
    Becker B. Diamox and the therapy of glaucoma. Am J Ophthalmol. 1954;38:16–17.Google Scholar
  3. 3.
    Ponticello GS, Sugrue MF, Plazonnet B, et al. Dorzolamide, a 40-year wait: from an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. In: Borchardt RT, Freidinger RM, Sawyer TK, Smith PL, eds. Integration of Pharmaceutical Discovery and Development. New York, NY: Plenum; 1998:555–574.Google Scholar
  4. 4.
    Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the rabbit eye. Invest Ophthalmol Vis Sci. 1977;16:1125–1134.PubMedGoogle Scholar
  5. 5.
    Camras CB, Bito LZ. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied PGF2a. Curr Eye Res. 1981;1:205–209.CrossRefPubMedGoogle Scholar
  6. 6.
    Bito LZ. A new approach to the medical management of glaucoma, from the bench to the clinic and beyond. Invest Ophthalmol Vis Sci. 2001;42:1126–1133.PubMedGoogle Scholar
  7. 7.
    Giuffrè G. The effects of prostaglandin F2a in the human eye. Graefes Arch Clin Exp Ophthalmol. 1985;222:139–141.CrossRefPubMedGoogle Scholar
  8. 8.
    Stjernschantz JW. From PGF2a-isopropyl-ester to latanoprost: a review of the development of Xalatan. Invest Ophthalmol Vis Sci. 2001;42:1134–1145.PubMedGoogle Scholar
  9. 9.
    Villumsen J, Alm A, Söderström M. Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma. Br J Ophthalmol. 1989;73(12):975–979.CrossRefPubMedGoogle Scholar
  10. 10.
    Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421–432.CrossRefPubMedGoogle Scholar
  11. 11.
    Hellberg MR, McLaughlin MA, Sharif NA, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47(Suppl 1):S13-S33.CrossRefPubMedGoogle Scholar
  12. 12.
    Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714–720.PubMedGoogle Scholar
  13. 13.
    Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48–56.PubMedGoogle Scholar
  14. 14.
    Chauhan BC, Mikelberg FS, Balaszi AG. Canadian Glaucoma Study 2. Risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008;126(8):1030–1036.CrossRefPubMedGoogle Scholar
  15. 15.
    Spilker B. Multinational Pharmaceutical Companies: Principles and Practices. 2nd ed. New York, NY: Raven; 1994.Google Scholar
  16. 16.
    Ng R. Drugs from Discovery to Approval. Hoboken, NJ: John; 2004.Google Scholar
  17. 17.
    Campbell JJ. Understanding Pharma - A Primer on How Pharmaceutical Companies Really Work. Raleigh, NC: Pharmaceutical Institute; 2005.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Michael Bergamini
    • 1
  1. 1.Department of Pharmacology and NeuroscienceUniversity of North Texas Health Services CenterFort WorthUSA

Personalised recommendations